Clinical trial NCT01341522: Clinical Evaluation of the Sorin Group's REPLY MR-conditional Pacing System
Official title: Clinical Evaluation of the Sorin Group's REPLY MR-conditional Pacing System
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Dual-chamber Pacemaker Placement
Lead sponsor: LivaNova
Sponsor class: INDUSTRY
First posted: 2011-04-25
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Permanent cardiac pacemakers have represented a contraindication to Magnetic Resonance Imaging (MRI). Strong static, gradient and radiofrequency fields used for MRI are thought to be detrimental to pacemaker function and possibly cause harm to patients undergoing MRI examinations. A previous study has shown that MRI is indicated in 17% of all patients with pacemakers within 12 months of device placement , which demonstrates the need of practical, safe approach for performing MRI on pacemaker patients. A new Reply MR-conditional pacing system is developed by Sorin Group for safe use in the MRI environment. The new pacing system is composed by the Reply pacemaker and the Filtrea bradycardia pacing leads. This study intends to demonstrate the safety and the efficacy in the MRI environment of the Sorin Group Reply MR-conditional pacing system.


Eligibility criteria: Inclusion Criteria:

* Patients who are candidates for dual-chamber pacemaker primo-implantation
* Patients who have indication for implantation of a dual-chamber pacemaker according to the American College of Cardiology and the American Heart Association
* Patients who are able and willing to undergo elective MRI scanning
* Patients who are scheduled for implant of a Reply DR pacemaker and Filtrea lead(s) only
* Patients who provided signed and dated informed consent

Exclusion Criteria:

* Non MR-compatible device or material implant
* Chronic atrial fibrillation (for atrial lead evaluation)
* Incessant ventricular tachyarrhythmia (for ventricular lead evaluation)
* Inability to understand the purpose of the study or refusal to co-operate
* Unavailability for scheduled follow-ups at the implanting centre
* Already included in another clinical study that could affect the results of this study
* Inability or refusal to provide informed consent
* Patient is minor (less than 18-year old)
* Patient is pregnant (women of childbearing potential should have a negative pregnancy test prior to enrolment);
* Patient has life expectancy of less than 1 year
* Patient is forfeiture of freedom or under guardianship
* Any patient to whom a contra-indication from device and lead labeling applies

Primary outcomes:
measure: assess the pacing system-, MRI- and implant procedure-related complication-free rate
timeFrame: 1 month
measure: assess atrial and ventricular lead-related complication-free rate
timeFrame: 3 months
measure: compare the changes in atrial and ventricular pacing thresholds before and after MRI, between MRI and control groups
timeFrame: 3 months
measure: compare the changes in atrial and ventricular sense amplitude after MRI between MRI and control groups
timeFrame: 3 months
Secondary outcomes:
measure: Summarize all implant procedure, pacing system- and MRI procedure-related adverse events
timeFrame: 12 months
measure: Summarize atrial and ventricular electrical performances
timeFrame: 3 months
measure: Summarize atrial and ventricular lead handling
timeFrame: 2 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Queen Elizabeth BIRMINGHAM UNITED KINGDOM
name: Francisco LEYVA, Dr
role: PRINCIPAL_INVESTIGATOR
References: